Kazia Therapeutics will meet with the FDA in December 2024 to discuss potential registration pathways for paxalisib in newly diagnosed glioblastoma multiforme (GBM).
Kazia Therapeutics presented its corporate overview in November 2024, highlighting its focus on developing innovative oncology drugs, including paxalisib and EVT801.
Kazia Therapeutics presented Phase 1 data for EVT801, a VEGFR3 inhibitor, at the Ovarian Cancer Research Symposium, showcasing its potential in treating advanced ovarian cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.